Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Damora Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
DMRA
Nasdaq
2834
www.damoratx.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Damora Therapeutics, Inc.
Should Trial Launch Require Action From Damora Therapeutics (DMRA) Investors?
- Nov 5th, 2026 8:19 pm
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Nov 5th, 2026 2:01 pm
Damora Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
- Nov 4th, 2026 2:06 pm
Damora Therapeutics to Present New Preclinical Data Highlighting Potentially Best-in-Class Pan-Mutant Activity of DMR-001 in Mutant Calreticulin (mutCALR)-driven Myeloproliferative Neoplasms (MPN) at the American Society of Hematology (ASH) 2026 Annual Meeting
- Nov 4th, 2026 7:00 am
Damora Therapeutics (DMRA) Stock Looks Above Fair Value On Book Value
- Oct 10th, 2026 8:21 am
Damora Therapeutics (DMRA) Climbed, So What Is Drawing Attention Now?
- Oct 9th, 2026 11:10 pm
Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
- Aug 10th, 2026 2:05 pm
Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis
- Aug 5th, 2026 6:00 am
Damora Announces Redomestication from Delaware to Cayman Islands
- Jul 17th, 2026 6:00 am
Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
- May 12th, 2026 2:05 pm
What Damora Therapeutics (DMRA)'s CEO Shake-Up and Finance Refresh Means For Shareholders
- May 8th, 2026 3:30 pm
Damora Therapeutics (DMRA) Appoints Jennifer Jarrett as President, Chief Executive Officer
- May 5th, 2026 11:05 am
Assessing Damora Therapeutics (DMRA) Valuation After CFO Transition And Recent Share Price Momentum
- May 5th, 2026 8:10 am
Scroll